Literature DB >> 15520311

Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin-converting enzyme is related to enhanced breakdown of N-acetyl-Ser-Asp-Lys-Pro and increased phosphorylation of Smad2/3.

Saraswati Pokharel1, Peter P van Geel, Umesh C Sharma, Jack P M Cleutjens, Holger Bohnemeier, Xiao-Li Tian, Heribert Schunkert, Harry J G M Crijns, Martin Paul, Yigal M Pinto.   

Abstract

BACKGROUND: Although increased activity of angiotensin-converting enzyme (ACE) has been associated with increased cardiac collagen, no studies to date have established a direct cause-and-effect relation between the two. METHODS AND
RESULTS: We used transgenic rats that overexpress human ACE selectively in the myocardium. Two independent heterozygous transgenic rat lines were studied, one expressing 2 to 3 copies (L1172) and the other expressing 5 to 10 copies (L1173) of the ACE transgene. These rats were normotensive but developed a proportionate increase in myocardial collagen depending on the ACE gene dose (up to 2.5-fold, P<0.01), but cardiac angiotensin II levels remained normal, whereas collagen content reversed to control levels on ACE inhibition. To explain these changes, we investigated N-acetyl-Ser-Asp-Lys-Pro (AcSDKP), an alternative substrate that is catabolized exclusively by ACE. Increased cardiac expression of ACE was paralleled by a reciprocal decrease in cardiac AcSDKP and a proportionate increase in phosphorylated Smad2 and Smad3, all of which normalized after both ACE inhibition and AcSDKP infusion. Furthermore, a functional link of this signaling cascade was demonstrated, because AcSDKP inhibited Smad3 phosphorylation in a dose-dependent manner in cultured cardiac fibroblasts and in vivo.
CONCLUSIONS: Our findings suggest that increased cardiac ACE activity can increase cardiac collagen content by degradation of AcSDKP, an inhibitor of the phosphorylation of transforming growth factor-beta signaling molecules Smad2 and Smad3. This implies that the antifibrotic effects of ACE inhibitors are mediated in part by increasing cardiac AcSDKP, with subsequent inhibition of Smad 2/3 phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15520311     DOI: 10.1161/01.CIR.0000147180.87553.79

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  25 in total

1.  Fast atrial fibrillation and caecal volvulus--a case report and evidence based management.

Authors:  Alexander Liu; Edward Nicol
Journal:  BMJ Case Rep       Date:  2011-12-20

Review 2.  Re-employment of developmental transcription factors in adult heart disease.

Authors:  Toru Oka; Jian Xu; Jeffery D Molkentin
Journal:  Semin Cell Dev Biol       Date:  2006-11-24       Impact factor: 7.727

Review 3.  Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation.

Authors:  Christopher E Woods; Jeffrey Olgin
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

4.  N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research.

Authors:  Tang-Dong Liao; Xiao-Ping Yang; Martin D'Ambrosio; Yanlu Zhang; Nour-Eddine Rhaleb; Oscar A Carretero
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

5.  N-acetyl-Ser-Asp-Lys-Pro inhibits interleukin-1β-mediated matrix metalloproteinase activation in cardiac fibroblasts.

Authors:  Nour-Eddine Rhaleb; Saraswati Pokharel; Umesh C Sharma; Hongmei Peng; Edward Peterson; Pamela Harding; Xiao-Ping Yang; Oscar A Carretero
Journal:  Pflugers Arch       Date:  2013-05-08       Impact factor: 3.657

6.  A Small Peptide Ac-SDKP Inhibits Radiation-Induced Cardiomyopathy.

Authors:  Umesh C Sharma; Swati D Sonkawade; Joseph A Spernyak; Sandra Sexton; Juliane Nguyen; Suraj Dahal; Kristopher M Attwood; Anurag K Singh; Jop H van Berlo; Saraswati Pokharel
Journal:  Circ Heart Fail       Date:  2018-08       Impact factor: 8.790

7.  Antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline on bile duct ligation induced liver fibrosis in rats.

Authors:  Lei Zhang; Lei-Ming Xu; Yuan-Wen Chen; Qian-Wen Ni; Min Zhou; Chun-Ying Qu; Yi Zhang
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

8.  Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse.

Authors:  Christopher F Spurney; Hee-Jae Cha; Arpana Sali; Gouri S Pandey; Emidio Pistilli; Alfredo D Guerron; Heather Gordish-Dressman; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  PLoS One       Date:  2010-01-29       Impact factor: 3.240

Review 9.  Ablation of long-standing persistent atrial fibrillation.

Authors:  Behram P Mody; Anoshia Raza; Jason Jacobson; Sei Iwai; Daniel Frenkel; Rhadames Rojas; Wilbert S Aronow
Journal:  Ann Transl Med       Date:  2017-08

10.  Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension.

Authors:  Hongmei Peng; Oscar A Carretero; Tang-Dong Liao; Edward L Peterson; Nour-Eddine Rhaleb
Journal:  Hypertension       Date:  2007-02-05       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.